Evidence map›Paper›PMID 32938956›Full record

ArticleScientific reports2020

Unique combination of clinical features in a large cohort of 100 patients with retinitis pigmentosa caused by FAM161A mutations.

Avigail Beryozkin, Samer Khateb, Carlos Alberto Idrobo-Robalino, Muhammad Imran Khan, Frans P M Cremers, Alexey Obolensky, Mor Hanany, Eedy Mezer, Itay Chowers, Hadas Newman and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. "ArmedFrontiers in cell and developmental biology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Gene augmentation therapy attenuates retinal degeneration in a knockout mouse model of Fam161a retinitis pigmentosa.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  8. Gene augmentation in FAM161A ciliopathy: Toward functional vision rescue.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Avigail BeryozkinDepartment of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University Jerusalem, Jerusalem, Israel.
Samer KhatebDepartment of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University Jerusalem, Jerusalem, Israel.
Carlos Alberto Idrobo-RobalinoDepartment of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University Jerusalem, Jerusalem, Israel.
Muhammad Imran KhanDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Frans P M CremersDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Alexey ObolenskyDepartment of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University Jerusalem, Jerusalem, Israel.
Mor HananyDepartment of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University Jerusalem, Jerusalem, Israel.
Eedy MezerDepartment of Ophthalmology, Rambam Health Care Campus, Haifa, Israel.
Itay ChowersDepartment of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University Jerusalem, Jerusalem, Israel.
Hadas NewmanSackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Tamar Ben-YosefRappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Dror Sharon *Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University Jerusalem, Jerusalem, Israel. dror.sharon1@mail.huji.ac.il.
Eyal Banin *Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University Jerusalem, Jerusalem, Israel. banine@cc.huji.ac.il.
Hadassah Medical Center · ILRadboud University Nijmegen · NLTechnion – Israel Institute of Technology · ILTel Aviv Sourasky Medical Center · IL

Funding

Foundation Fighting Blindness BR-GE-0214-0639
6 · The paper itself

Abstract

FAM161A mutations are the most common cause of autosomal recessive retinitis pigmentosa in the Israeli-Jewish population. We aimed to characterize the spectrum of FAM161A-associated phenotypes and identify characteristic clinical features. We identified 114 bi-allelic FAM161A patients and obtained clinical records of 100 of these patients. The most frequent initial symptom was night blindness. Best-corrected visual acuity was largely preserved through the first three decades of life and severely deteriorated during the 4th-5th decades. Most patients manifest moderate-high myopia. Visual fields were markedly constricted from early ages, but maintained for decades. Bone spicule-like pigmentary changes appeared relatively late, accompanied by nummular pigmentation. Full-field electroretinography responses were usually non-detectable at first testing. Fundus autofluorescence showed a hyper-autofluorescent ring around the fovea in all patients already at young ages. Macular ocular coherence tomography showed relative preservation of the outer nuclear layer and ellipsoid zone in the fovea, and frank cystoid macular changes were very rare. Interestingly, patients with a homozygous nonsense mutation manifest somewhat more severe disease. Our clinical analysis is one of the largest ever reported for RP caused by a single gene allowing identification of characteristic clinical features and may be relevant for future application of novel therapies.

Indexed as

MutationAdolescentAdultAgedAged, 80 and overAllelesChildChild, PreschoolCohort StudiesElectroretinographyEye ProteinsFemaleFundus OculiGenes, RecessiveHumansIsraelEye ProteinsFAM161A protein, human

Identifiers

PMID32938956
PMCPMC7495424
OpenAlexW3087377005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.